LitCovid-sentences  

PMC:7558233 / 40056-43460 JSONTXT 4 Projects

Annnotations TAB TSV DIC JSON TextAE

Id Subject Object Predicate Lexical cue
T236 0-22 Sentence denotes 9 Vaccine development
T237 23-161 Sentence denotes Despite tremendous global efforts to contain the outbreak and rapid advances in therapeutics, few targeted approaches have been available.
T238 162-364 Sentence denotes Given the rapid transmission and the rapid decay of antibody titers [113], vaccines that can induce strong anti-SARS-CoV-2 immune responses are urgently needed to achieve global containment of COVID-19.
T239 365-468 Sentence denotes Vaccine development has benefited from the early release of the complete genome sequence of SARS-CoV-2.
T240 469-638 Sentence denotes As of 3 September 2020, according to the WHO, 33 vaccine candidates are at different stages of clinical development, six of which are at phase III clinical trials [114].
T241 639-748 Sentence denotes On 22 July 2020, China approved the use of two inactivated COVID-19 vaccines developed by Sinovac Biotech Co.
T242 749-760 Sentence denotes Ltd. [115].
T243 761-882 Sentence denotes Another adenovirus vector-based SARS-CoV-2 vaccine was approved by the administrative office of Russia on 10 August 2020.
T244 883-982 Sentence denotes U.S. authorities have recently announced the pending approval of a vaccine by the end of this year.
T245 983-1187 Sentence denotes In public health emergencies, such as the COVID-19 pandemic, regulators are expected to act quickly to support accelerated vaccine development through the introduction of increased regulatory flexibility.
T246 1188-1438 Sentence denotes To guide the accelerated vaccine development and approval for COVID-19, the Chinese regulatory agencies and the National Medical Products Administration (NMPA) have issued seven guidelines since March 2020 to provide a roadmap and requirements [116].
T247 1439-1588 Sentence denotes Moreover, the Chinese NMPA has formulated a special scheme to synchronize the protocol reviewing process with the research and development processes.
T248 1589-1775 Sentence denotes Consequently, completion of the vaccine development and the review may take place simultaneously so that the vaccine development can proceed to clinical application without major delays.
T249 1776-1939 Sentence denotes For example, the NMPA completed the review process of the Sinopharm COVID-19 vaccine application within just 24 h, although such a review would normally take 60 d.
T250 1940-2174 Sentence denotes Thus far, there have been ten Chinese COVID-19 vaccine candidates in the pipeline of clinical trials [114], [117], [118], [119], [120], [121], [122], [123], in four of which international phase III clinical trials have been initiated.
T251 2175-2274 Sentence denotes Furthermore, more than 21 preclinical projects may have the potential to move into clinical trials.
T252 2275-2522 Sentence denotes Nearly all of the current human vaccines are based on two major platforms: the virus-based (inactivated/attenuated) vaccine platform and the recombinant protein-based (subunit/virus-like particle (VLP)) vaccine platform [120], [124], [125], [126].
T253 2523-2649 Sentence denotes Four “inactivated virus vaccines” are in post-phase II clinical trials, and two of these have been approved for emergency use.
T254 2650-2850 Sentence denotes This major achievement from the “inactivated virus vaccine platform” in China was made possible by the early development of the inactivated enterovirus 71 and inactivated poliovirus vaccines in China.
T255 2851-3132 Sentence denotes A replication-defective human adenovirus type-5-based COVD-19 vaccine encoding the full S protein of SARS-CoV-2 as a subunit-based vaccine was found to successfully elicit cellular immune responses via single-dose inoculation through the intramuscular or intranasal administration.
T256 3133-3242 Sentence denotes This vaccine could effectively prevent SARS-CoV-2 infection in the higher and lower respiratory tracts [127].
T257 3243-3404 Sentence denotes Moreover, mucosal vaccination might be more effective in preventing viral replication in the upper respiratory tract, as compared with intramuscular vaccination.